KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) EBITDA (2016 - 2025)

Historic EBITDA for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $163.1 million.

  • BeOne Medicines' EBITDA rose 23562.88% to $163.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.7 million, marking a year-over-year increase of 12093.54%. This contributed to the annual value of -$568.2 million for FY2024, which is 5295.34% up from last year.
  • Per BeOne Medicines' latest filing, its EBITDA stood at $163.1 million for Q3 2025, which was up 23562.88% from $87.9 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' EBITDA ranged from a high of $190.6 million in Q4 2021 and a low of -$474.8 million during Q2 2021
  • In the last 5 years, BeOne Medicines' EBITDA had a median value of -$261.3 million in 2024 and averaged -$209.5 million.
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 73175.99% in 2022, then skyrocketed by 23562.88% in 2025.
  • Over the past 5 years, BeOne Medicines' EBITDA (Quarter) stood at $190.6 million in 2021, then tumbled by 345.92% to -$468.6 million in 2022, then increased by 18.1% to -$383.8 million in 2023, then skyrocketed by 79.31% to -$79.4 million in 2024, then surged by 305.37% to $163.1 million in 2025.
  • Its EBITDA stands at $163.1 million for Q3 2025, versus $87.9 million for Q2 2025 and $11.1 million for Q1 2025.